Kotra Industries BhdXKLS:0002 84 Net Margin % is 15.43% as of Mar. 2026, which is 5% below its 10-year median of 16.25. GuruFocus rates XKLS:0002 with a GF Score™ of 84/100 and a GF Value™ of RM4.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 956 Drug Manufacturers companies, Kotra Industries Bhd ranks better than 82.64% on this metric.
The historical rank and industry rank for Kotra Industries Bhd's Net Margin % or its related term are showing as below:
XKLS:0002'
s Net Margin % Range Over the Past 10 Years
Min: 4.84 Med: 16.25 Max: 29.87
Current: 16.99
XKLS:0002's Net Margin % is ranked better than 82.64% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs XKLS:0002: 16.99
Kotra Industries Bhd (XKLS:0002) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Kotra Industries Bhd Net Margin % Related Terms
Kotra Industries Bhd Net Margin % Historical Data
* Premium members only.
The historical data trend for Kotra Industries Bhd's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0002 vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kotra Industries Bhd's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kotra Industries Bhd Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kotra Industries Bhd's Net Margin % distribution charts can be found below:
* The bar in red indicates where Kotra Industries Bhd's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kotra Industries Bhd (XKLS:0002) has a Net Margin % of 15.43% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Kotra Industries Bhd and its competitors. This is near median its historical median of 16.25. Over the past decade, Kotra Industries Bhd's Net Margin % has ranged from 4.84 to 29.87. According to the industry distribution chart, Kotra Industries Bhd ranks #166 out of 956 companies in the Drug Manufacturers industry, placing it in the top 17.4%.
Is Kotra Industries Bhd's Net Margin % too high?
Kotra Industries Bhd's current Net Margin % of 15.43% is near median its 10-year median of 16.25. Over the past 10 years, this metric has ranged from a low of 4.84 to a high of 29.87. The Drug Manufacturers industry median Net Margin % is 5.56. Kotra Industries Bhd's value of 15.43% is 177.5% above this industry median. Based on the distribution chart, Kotra Industries Bhd ranks #166 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kotra Industries Bhd has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kotra Industries Bhd's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kotra Industries Bhd ranks #166 out of 956 companies for Net Margin %. This places Kotra Industries Bhd in the top 17% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Kotra Industries Bhd's value of 15.43% is 177.5% above this benchmark. Historically, Kotra Industries Bhd's own Net Margin % has ranged from 4.84 to 29.87 over the past decade. While the company's 10-year median is 16.25 vs. the industry median of 5.56, Kotra Industries Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kotra Industries Bhd's current Net Margin % of 15.43% is 177.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Kotra Industries Bhd and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kotra Industries Bhd's current Net Margin % is 15.43%, which is near median its own 10-year median of 16.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kotra Industries Bhd stock overvalued right now?
Based on GuruFocus' analysis, Kotra Industries Bhd (XKLS:0002) is currently considered Modestly Undervalued. The stock's GF Value™ is RM4.33, compared to a current price of RM3.71 — trading 14.3% below its estimated fair value. The current Net Margin % is 15.43%, which is near median its 10-year median of 16.25 and 177.5% above the Drug Manufacturers industry median of 5.56. Kotra Industries Bhd's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Kotra Industries Bhd (XKLS:0002), the current Net Margin % is 15.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kotra Industries Bhd (XKLS:0002) Overvalued in 2026?
Based on GuruFocus' analysis, Kotra Industries Bhd stock appears to be undervalued.
The current stock price of RM3.71 is trading 14.3% below its estimated GF Value™ of RM4.33.
GuruFocus considers Kotra Industries Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0002:
Net Margin %: 15.43% (near median its 10-year median of 16.25)
GF Value™: RM4.33 vs. price of RM3.71 (14.3% below fair value)
Industry Position: 177.5% above the Drug Manufacturers median (#166 of 956)
No single metric tells the full story. See the XKLS:0002 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kotra Industries Bhd is a Malaysian pharmaceutical company engaged in the development, manufacturing, and supply of pharmaceutical and healthcare products supporting all life stages. Its portfolio includes life-saving medicines, OTC supplements, and nutrition products. The Group markets three core brands: Appeton, offering health supplements and nutrition across all age groups; Vaxcel, providing injectable medicines for infectious diseases, kidney care, and gastroenterology; and Axcel, specializing in oral and topical medicines for paediatrics, dermatology, and infectious diseases. The company operates in Malaysia and overseas, with the majority of revenue derived from Malaysia.
84GF Score
Get the complete analysis for XKLS:0002
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0002 has been successfully added to your 
